HK Stock Movement | INNOVENT BIO (01801) Rises Over 4% as Q3 Total Product Revenue Grows ~40% YoY

Stock News

Oct 31

INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion in Q3 2025, maintaining robust year-on-year growth of approximately 40%, driven by dual growth engines in oncology and comprehensive pipelines.

To date, INNOVENT BIO has secured approvals for 16 products, with 2 candidates under review by China's NMPA and 4 novel drug molecules in Phase 3 or pivotal clinical studies. Additionally, around 15 new drug candidates have entered clinical trials.

2025 marks a pivotal year for the company as it transitions into a new phase of dual-engine growth and global innovation, steadily advancing toward its vision of becoming a world-class biopharmaceutical company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106242653"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106242653\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106242653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106242653","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | INNOVENT BIO (01801) Rises Over 4% as Q3 Total Product Revenue Grows ~40% YoY","media":"Stock News","content":"<p>INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion in Q3 2025, maintaining robust year-on-year growth of approximately 40%, driven by dual growth engines in oncology and comprehensive pipelines.</p>\n<p>To date, INNOVENT BIO has secured approvals for 16 products, with 2 candidates under review by China's NMPA and 4 novel drug molecules in Phase 3 or pivotal clinical studies. Additionally, around 15 new drug candidates have entered clinical trials.</p>\n<p>2025 marks a pivotal year for the company as it transitions into a new phase of dual-engine growth and global innovation, steadily advancing toward its vision of becoming a world-class biopharmaceutical company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOVENT BIO (01801) Rises Over 4% as Q3 Total Product Revenue Grows ~40% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOVENT BIO (01801) Rises Over 4% as Q3 Total Product Revenue Grows ~40% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion in Q3 2025, maintaining robust year-on-year growth of approximately 40%, driven by dual growth engines in oncology and comprehensive pipelines.</p>\n<p>To date, INNOVENT BIO has secured approvals for 16 products, with 2 candidates under review by China's NMPA and 4 novel drug molecules in Phase 3 or pivotal clinical studies. Additionally, around 15 new drug candidates have entered clinical trials.</p>\n<p>2025 marks a pivotal year for the company as it transitions into a new phase of dual-engine growth and global innovation, steadily advancing toward its vision of becoming a world-class biopharmaceutical company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828474.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC A","start_time":0,"source_url":"","article_id":"1106242653","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106242653","pubTimestamp":1761875652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1583":"高瓴概念","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1589":"北水核心资产","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","01801":"信达生物","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"港股动向|信达生物(01801)升超4%Q3产品总收入同比增长约40%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"INNOVENT BIO (01801) surged more than 4%, gaining 4.58% to HK$84.4 by the time of writing, with a trading volume of HK$330 million. The company reported total product revenue exceeding RMB3.3 billion in Q3 2025, maintaining robust year-on-year growth of approximately 40%, driven by dual growth engines in oncology and comprehensive pipelines.\nTo date, INNOVENT BIO has secured approvals for 16 products, with 2 candidates under review by China's NMPA and 4 novel drug molecules in Phase 3 or pivotal clinical studies. Additionally, around 15 new drug candidates have entered clinical trials.\n2025 marks a pivotal year for the company as it transitions into a new phase of dual-engine growth and global innovation, steadily advancing toward its vision of becoming a world-class biopharmaceutical company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}